NEW YORK (GenomeWeb News) – GenMark Diagnostics today provided second-quarter revenue guidance and raised its full-year 2012 revenue guidance.

For the quarter ending June 30, the Carlsbad, Calif.-based molecular testing firm said that revenues are anticipated to fall between $3.2 million and $3.6 million. Full-year 2012 revenues are now expected to top $15 million. GenMark said in its fourth-quarter and full-year 2011 earnings announcement that 2012 revenues would exceed $10 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.